Candel therapeutics announces an upcoming presentation at the aacr annual meeting unveiling new cancer immunotherapy candidate

Needham, mass., march 05, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the company will present a poster presentation at the american association for cancer research (aacr) annual meeting taking place april 5-10, 2024, in san diego, ca. the presentation will describe the second candidate from the enlighten™ discovery platform, a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors. this abstract presentation at aacr accelerates the milestone associated with the unveiling of the second enlighten™ program, which was originally planned for the third quarter of 2024.
CADL Ratings Summary
CADL Quant Ranking